NR3C2 and obesity disorder: This study demonstrates that long-term mineralocorticoid receptor blockade with spironolactone decreased coronary TRPC expression, atherosclerosis, and hypercontractility in the Ossabaw pig model of metabolic syndrome without impacting obesity or glucose tolerance.